Lysophosphatidic acid receptor isoforms expression in prostate cancer cells is differentially regulated by the CYP17A1 inhibitor abiraterone and depends on the androgen receptor

Matthias S Stope, Robert Mandelkow, Daniela Brunnert, Martin Weiss, Martin Burchardt


Prostate cancer (PC) treatment with steroid synthesis inhibitor, abiraterone acetate (AA) provides substantial survival advantages in advanced PC therapy. Owing to AA's anti-proliferative efficacy, even in the absence of androgen receptor (AR), the molecular mode of action is suspected to be a result of simultaneously targeted cellular factors. The present study demonstrated a differentially regulated expression of proliferative lysophosphatidic acid receptor (LPAR) isoforms in androgen receptor AR-positive LNCaP cells incubated with AA. Since LPAR regulation in AR-negative PC-3 cells is unaffected, it could be assumed that AA’s anticancer activity on LPAR expression depends on AR signaling cascades.


prostate cancer; lysophosphatidic acid receptor; abiraterone; CYP17A1; steroid synthesis

Full Text:



Carthon B, Rossi PJ. Update on systemic therapy for advance prostate cancer. Curr Probl Cancer 2015; 39(1): 52–62. doi: 10.1016/j.currproblcancer.2014.11.009.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005. doi: 10.1056/NEJMoa1014618.

Miller WL. Steroidogenic enzymes. In: Flück CE, Miller W, (editors). Disorders of the human adrenal cortex. Basel: Karger AG; 2008. p. 1–18. doi: 10.1159/isbn.978-3-8055-8581-1.

Stope MB, Schubert T, Staar D, Rönnau C, Streitbörger A, Kroeger N, Kubisch C, Zimmerman U, Walther R, Burchardt M. Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. World J Urol 2012; 30(3): 327–331. doi: 10.1007/s00345-012-0843-z.

Weiss M, Burchardt M, Stope MB. Master of puppets in prostate cancer: Heat shock protein 27 is pulling androgen receptor’s strings. Cancer Cell Microenviron 2014; 1: e287. doi: 10.14800/ccm.287.

Tsujiuchi T, Araki M, Hirane M, Dong Y, Fukushima N. Lysophosphatidic acid receptors in cancer pathobiology. Histol Histopathol 2014; 29(3): 313–321.

Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J, Kim YK, Kang J, Park CG, Han JW, Lee HY. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012; 31: 4279–4289. doi: 10.1038/onc.2011.595.

Shin SH, Kwon YW, Heo SC, Jeong GO, Kim BR, Seo EJ, Kim JH. Krüppel-like factor 4 mediates lysophosphatidic acid-stimulated migration and proliferation of PC3M prostate cancer cells. Exp Mol Med 2014; 46: e104. doi: 10.1038/emm.2014.34.

Lin CE, Chen SU, Lin CC, Chang CH, Lin YC, Tai YL, Shen TL, Lee H. Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. PLoS One 2012; 7(7): e41096. doi: 10.1371/journal.pone.0041096.

Daaka Y. Mitogenic action of LPA in prostate. BBA-Mol Cell Biol L 2002; 1582(1-3): 265–269. doi: 10.1016/S1388-1981(02)00180-4.

Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-κB. Prostate 2004; 61(2): 105–113. doi: 10.1002/pros.20083.

González-Arenas A, Avendaño-Vázquez SE, Cabrera-Wrooman A, Tapia-Carrillo D, Larrea F, García-Becerra R, García-Sáinz JA. Regulation of LPA receptor function by estrogens. BBA-Mol Cell Res 2008; 1783(2): 253–262. doi: 10.1016/j.bbamcr.2007.11.014.

Sumida H, Nakamura K, Yanagida K, Ohkawa R, Asano Y, Kadono T, Tamaki K, Igarashi K, Aoki J, Sato S, Ishii S, Shimizu T, Yatomi Y. Decrease in circulating autotaxin by oral administration of prednisolone. Clin Chim Acta 2013; 415: 74–80. doi: 10.1016/j.cca.2012.10.003.

Bex A, Lümmen G, Rembrink K, Otto T, Metz K, Rübben H. Influence of pertussis toxine on local progression and metastasis after orthotopic implantation of the human prostate cancer cell line PC3 in nude mice. Prostate Cancer Prostatic Dis 1999; 2(1): 36–40. doi: 10.1038/sj.pcan.4500286.

Grossebrummel H, Peter T, Mandelkow R, Weiss M, Muzzio D, Zimmerman U, Walther R, Jensen F, Knabbe C, Zygmunt M, Burchardt M, Stope MB. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol 2016; 48(2): 793–800. doi: 10.3892/ijo.2015.3274.

Brünnert D, Sztachelska M, Bornkessel F, Treder N, Wolczynski S, Goyal P, Zygmunt M. Lysophosphatidic acid and sphingosine 1-phosphate metabolic pathways and their receptors are differentially regulated during decidualization of human endometrial stromal cells. Mol Hum Reprod 2014; 20(10): 1016–1025. doi: 10.1093/molehr/gau051.

Stope MB, Kunkel C, Kories C, Schmidt M, Michel MC. Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. Biochem Pharmacol 2003; 66(11): 2099–2105. doi: 10.1016/S0006-2952(03)00580-X.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407–6415. doi: 10.1158/0008-5472.CAN-07-5997.

Yin L, Hu Q. CYP17 inhibitors–abiraterone, C17, 20-lyase inhibitors and multi-targeting agents. Nat Rev Urol 2014; 11: 32–42. doi: 10.1038/nrurol.2013.274.

Zhang H, Sun L, Xiao X, Xie R, Liu C, Wang Y, Wei Y, Zhang H, Liu L. Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells. Cancer Sci 2014; 105(9): 1109–1115. doi: 10.1111/cas.12483.

Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal Transduct Res 2015; 35(6): 578–584. doi: 10.3109/10799893.2015.1026444.

Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem 2004; 73: 321–354. doi: 10.1146/annurev.biochem.73.011303.073731.

Luquain C, Sciorra VA, Morris AJ. Lysophosphatidic acid signaling: How a small lipid does big things. Trends Biochem Sci 2003; 28(7): 377–383. doi: 10.1016/S0968-0004(03)00139-7.

Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004; 279: 20555–20558. doi: 10.1074/jbc.R400013200.

Zhao H, Ramos CF, Brooks JD, Peehl DM. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 2007; 210(1): 111–121. doi: 10.1002/jcp.20828.

Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Brit J Cancer 2010; 102: 941–946. doi: 10.1038/sj.bjc.6605588.

Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004; 279: 17634–17639. doi: 10.1074/jbc.M313927200.

David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P, Peyruchaud O. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One 2014; 9: e97771. doi: 10.1371/journal.pone.0097771.



  • There are currently no refbacks.

Copyright (c) 2018 Matthias S Stope, Robert Mandelkow, Daniela Brunnert, Martin Weiss, Martin Burchardt

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.